StageZero Life Sciences Ltd. 61N1.F Stock
StageZero Life Sciences Ltd. Price Chart
StageZero Life Sciences Ltd. 61N1.F Financial and Trading Overview
| StageZero Life Sciences Ltd. stock price | 0.02 EUR |
| Previous Close | 0.03 EUR |
| Open | 0.03 EUR |
| Bid | 0.03 EUR x N/A |
| Ask | 0.05 EUR x N/A |
| Day's Range | 0.03 - 0.03 EUR |
| 52 Week Range | 0.03 - 0.1 EUR |
| Volume | 16K EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 4.73M EUR |
| Beta (5Y Monthly) | 0.835497 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.11 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
61N1.F Valuation Measures
| Enterprise Value | 5.38M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.4549876 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 1.653 |
| Enterprise Value/EBITDA | -0.878 |
Trading Information
StageZero Life Sciences Ltd. Stock Price History
| Beta (5Y Monthly) | 0.835497 |
| 52-Week Change | -32.65% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.1 EUR |
| 52 Week Low | 0.03 EUR |
| 50-Day Moving Average | 0.04 EUR |
| 200-Day Moving Average | 0.05 EUR |
61N1.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 106.39M |
| Float | 92.3M |
| Short Ratio | N/A |
| % Held by Insiders | 2.61% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:8 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -195.65% |
| Gross Margin | -6.99% |
| EBITDA Margin | -188.30% |
Management Effectiveness
| Return on Assets (ttm) | -79.42% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 3.25M EUR |
| Revenue Per Share (ttm) | 0.03 EUR |
| Quarterly Revenue Growth (yoy) | -41.099% |
| Gross Profit (ttm) | N/A |
| EBITDA | -6124893 EUR |
| Net Income Avi to Common (ttm) | -12636774 EUR |
| Diluted EPS (ttm) | -0.11 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 36.3K EUR |
| Total Cash Per Share (mrq) | 0 EUR |
| Total Debt (mrq) | 2.01M EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.037 |
| Book Value Per Share (mrq) | -0.084 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -1507738 EUR |
| Levered Free Cash Flow (ttm) | 5.5K EUR |
Profile of StageZero Life Sciences Ltd.
| Country | Germany |
| State | ON |
| City | Richmond Hill |
| Address | 70 East Beaver Creek Road |
| ZIP | L4B 3B2 |
| Phone | N/A |
| Website | https://www.stagezerolifesciences.com |
| Industry | Diagnostics & Research |
| Sector(s) | Healthcare |
| Full Time Employees | 40 |
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.
Q&A For StageZero Life Sciences Ltd. Stock
What is a current 61N1.F stock price?
StageZero Life Sciences Ltd. 61N1.F stock price today per share is 0.02 EUR.
How to purchase StageZero Life Sciences Ltd. stock?
You can buy 61N1.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for StageZero Life Sciences Ltd.?
The stock symbol or ticker of StageZero Life Sciences Ltd. is 61N1.F.
Which industry does the StageZero Life Sciences Ltd. company belong to?
The StageZero Life Sciences Ltd. industry is Diagnostics & Research.
How many shares does StageZero Life Sciences Ltd. have in circulation?
The max supply of StageZero Life Sciences Ltd. shares is 191.04M.
What is StageZero Life Sciences Ltd. Price to Earnings Ratio (PE Ratio)?
StageZero Life Sciences Ltd. PE Ratio is now.
What was StageZero Life Sciences Ltd. earnings per share over the trailing 12 months (TTM)?
StageZero Life Sciences Ltd. EPS is -0.11 EUR over the trailing 12 months.
Which sector does the StageZero Life Sciences Ltd. company belong to?
The StageZero Life Sciences Ltd. sector is Healthcare.